METHOD
Data were collected from persons that were referred because they were
considered at increased risk of reacting adversely to the COVID-19
vaccine to the allergy departments in 5 referral hospitals between
January 2021 and September 2022 .
Adverse reactions on a previous COVID-19 vaccination were rated into two
categories: Moderate to severe manifested with generalized
urticaria/erythema , observed angioedema , hypotension or
stridor/decrease of oxygen saturation. Mild reactions manifested with
subjective or mild objective symptoms without any of the aforementioned
symptoms.
In cases, in which the allergist deemed an allergic cause of the
reaction possible, skin test were performed with the Covid-19 vaccine
and the excipients PEG and Polysorbate 80.
The study was approved by the Medical Ethical Committee of the UMCG and
the participating centers (METC number COVID19 vaccine hypersensitivity:
202100445) and written informed consent was waived. Statistical analyses
were performed using SPSS, version 27.